Adopting Novel Technologies To Improve Monoclonal Antibody Processes

New bispecific antibodies show better cancer-fighting promise as compared to traditional monoclonal antibodies, but they can create process difficulties. Avantor’s Dr. Nandu Deokar talks about four new-edge production technologies that better remove impurities, reduce aggregation and improve stability; including viral inactivation that overcomes REACH concerns, newly designed chromatography ligand, additives in wash step and novel excipients in formulation buffer.